Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INZ-701

Fusion protein · Protein replacement · developed by Inozyme Pharma

Phase 3 Most advanced trial (none active)
1 Registered trials

What is INZ-701?

INZ-701 (rhENPP1-Fc) is a recombinant fusion protein made of the extracellular domains of human ENPP1 coupled to an immunoglobulin gamma-1 Fc fragment. It is being studied in ENPP1 deficiency, autosomal recessive hypophosphatemic rickets, and generalized arterial calcification of infancy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
(rhENPP1-Fc).
Drug type
Fusion protein
Mechanism
Protein replacement
Therapy area
Metabolic, Musculoskeletal
Developer
Inozyme Pharma
In trials of
BMRN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
8ZH1P9LXW1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06046820 Phase 3 Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency Terminated BMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autosomal Recessive Hypophosphatemic RicketsEctonucleotide Pyrophosphatase/Phosphodiesterase1 DeficiencyGeneralized Arterial Calcification of Infancy

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.